Literature DB >> 8212827

Antibody response to whole-virus and split-virus influenza vaccines in successful ageing.

J E McElhaney1, G S Meneilly, K E Lechelt, B L Beattie, R C Bleackley.   

Abstract

The antibody response to influenza vaccination has been variably reported to be decreased in elderly individuals. To determine the effect of ageing alone on this antibody response, a group of carefully-screened healthy elderly subjects were compared with young adult controls. Antibody titres for several strains of influenza were measured before and after vaccination with whole-virus (WVV) and split-virus influenza vaccines (SVV) in two successive years. In general, the antibody response to WVV was greater than the response to SVV. Both groups showed a similar response to the H3N2 strain but the elderly group showed a lower response to the H1N1 and B strains of virus contained in the vaccine. Antibodies to older strains of influenza A but not B were stimulated by vaccination with SVV. In the elderly group, the response to older viral strains was relatively increased compared with newer strains. In contrast, the young control group had better antibody responses to the newer than to the older strains of influenza tested. Reductions in the antibody response to influenza vaccination may, therefore, be related to the phenomenon of original antigenic sin and the cohort effect of exposure to H1N1 during childhood in the elderly group studied. The increased immunogenicity of WVV must be considered in light of the current wide use of SVV in the elderly.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212827     DOI: 10.1016/0264-410x(93)90133-i

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population.

Authors:  T Menegon; V Baldo; C Bonello; D Dalla Costa; A Di Tommaso; R Trivello
Journal:  Eur J Epidemiol       Date:  1999-07       Impact factor: 8.082

2.  Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Ana Marie Landin; Mitch Phillips; Suzanne C Lechner; John G Ryan; Bonnie B Blomberg
Journal:  Vaccine       Date:  2010-10-23       Impact factor: 3.641

3.  Statement on influenza vaccination for the 1995-96 season. National Advisory Committee on Immunization.

Authors: 
Journal:  CMAJ       Date:  1995-09-01       Impact factor: 8.262

Review 4.  Vaccines for preventing influenza in people with cystic fibrosis.

Authors:  Poonam Dharmaraj; Rosalind L Smyth
Journal:  Cochrane Database Syst Rev       Date:  2014-03-06

5.  Statement on influenza vaccination for the 1994-95 season.

Authors: 
Journal:  CMAJ       Date:  1994-09-01       Impact factor: 8.262

6.  The age distribution of mortality due to influenza: pandemic and peri-pandemic.

Authors:  Tom Reichert; Gerardo Chowell; Jonathan A McCullers
Journal:  BMC Med       Date:  2012-12-12       Impact factor: 8.775

7.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

8.  An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen.

Authors:  Sue Stacy; Amanda Pasquali; Valerie L Sexton; Angelene M Cantwell; Ellen Kraig; Peter H Dube
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus.

Authors:  Victor C Huber; Loren H Kleimeyer; Jonathan A McCullers
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

Review 10.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.